BioM-COVID-19 exchange platform

BioM-COVID-19 exchange platform


In the context of the COVID-19 pandemic, it is of the utmost importance to accelerate the discovery and development of safe and more effective drugs and vaccines. Therefore we offer companies, research institutions and clinics an exchange platform for the search for partners, technologies and expertise in the context of COVID-19 research projects.

-> To the projects of the BioM-COVID-19 platform.

Please send your inquiries or search for cooperation partners or your offers regarding technologies or know-how within this BioM COVID-19 exchange platform-Formular by email to info@bio-m.org.

a)    We publish here your inquiry or offer.
b)    If the project is to be treated confidentially, we will be happy to take your suggestions and connect you with suitable partners from the academic or industrial sectors.

We would also like to draw your attention to the following additional contact points:

Forum Medtech Pharma
https://www.medtech-pharma.de/deutsch/branchen-infos/nachrichten---informationen/netzwerk-news/aufruf.aspx

Bayerisches Landesamt für Gesundheit und Lebensmittelsicherheit (LGL)
https://www.lgl.bayern.de/gesundheit/infektionsschutz/infektionskrankheiten_a_z/coronavirus/psa_bedarf.htm

BioRN-Exchange Platform
www.biorn.org/together-against

BIO.NRW COVID-19 Information- and Contact-Platform
www.bio.nrw.de

BIOWIN Wallonia Platform
https://biowin-cooperation-platform-covid-19.b2match.io/

Platform Projects

Clinical Trial / Regulatory Affairs Support

4G Clinical - Randomization and Trial Supply Management

4G Clinical - Randomization and Trial Supply Management

4G Clinical is offering global RTSM / IRT / IxRS / IWR services to bringing crucial medicines to those who need them, faster.

Contact: Mr. Martijn Princen, Vice President Global Business Development, martijn@remove-this.4gclinical.com, Tel: +49.151.5175.7680, www.4gclinical.com  

Bitcare - IT Know How and Software in Medical Informatics

Bitcare - IT Know How and Software in Medical Informatics

We offer IT expertise and technology. Particular focus is placed on IT security, data protection and integration of clinical systems.

Contact: Dr. Florian Kohlmayer, CEO, mail@remove-this.bitcare.de, Tel. +49 89 9430 1309, www.bitcare.de

Climedo - Software solution collecting clinical data for COVID-19 related projects

Climedo - Software solution collecting clinical data for COVID-19 related projects

Climedo Health offers its web-based platform for clinical data collection including digital patient diaries free of charge for medical practices, clinics, research institutes and non-profit organizations doing research related to COVID-19 (Coronavirus) / SARS-CoV-2. Climedo’s predefined digital eDiaries and ePROs (“electronic Patient Reported Outcomes”) will allow test subjects to submit potential symptoms, side effects or information on their state of wellbeing remotely via a mobile device or computer, even while being quarantined.

Contact: Sascha Ritz, Managing Director, Covid19@remove-this.climedo.de, www.climedo.de 

Johner Institut - COVID-19 regulatory support

Johner Institut - COVID-19 regulatory support

Support regarding CE marking of medical devices and IVD medical devices:
We offer to consult you 15 min free of charge, how to assess sensitivity in a fast approach and how to place your product on the market under "emergency use authorization".
Tag your message with @IVD and you will be forwarded to the IVD team by our dispatchers.

Contact: Dr. Sebastian Grömminger, Responsible consultant In vitro diagnostic medical devices, info@remove-this.johner-institut.de, Tel: +49 (7531) 94500 20, www.johner-institut.de 

Metronomia Clinical Research - biostatistical services, biostatistical consulting, clinical data management, support with authorities requests

Metronomia Clinical Research - biostatistical services, biostatistical consulting, clinical data management, support with authorities requests

Offer: Rapid clinical trial setup and statistical consulting - biostatistical services – clinical data management.
We are ready for rapid & high quality support of COVID-19 studies: Statistical consulting, eCRF setup & clinical data management. We’ll donate all fees from statistical consulting for COVID-19 studies to the University Hospital in Essen (https://spenden-für-corona.de) - our contribution to the Corona fight.

Contact: Rudolf Köhne-Volland, Managing Director, rkvolland@remove-this.metronomia.net, Tel: +49 (0) 89 82 92 65-222, www.metronomia.net

Profil - First-in-Human (phase 1) pivotal clinical trials on COVID-19 vaccines

Profil - First-in-Human (phase 1) pivotal clinical trials on COVID-19 vaccines

Profil is stepping up to this responsibility by offering support to companies developing vaccines against COVID-19. As one of the leading phase 1 units in Europe, we can offer experience with Europe's regulatory landscape as well as years of routine in conducting early phase trials in our two clinics in Germany. Combined with our team's previous experience working on novel vaccine developments this allows us to support companies looking for rapid and effective support in their clinical development.

Contact: Prof. Dr. Freimut Schliess, Director Science & Innovation,    Freimut.Schliess@remove-this.profil.com, Tel: +49 160 7035680, www.profil.com 

Proinnovera - Clinical Research Organization

Proinnovera - Clinical Research Organization

Proinnovera is available to manage clinical research projects related to COVID-19. We have over 20 years of experience in providing the following services in various therapeutic areas including vaccination studies:

  • Recruitment and Feasibility Management
  • Clinical Monitoring
  • Regulatory Services
  • Project Management
  • Medical Writing
  • Data Management and Statistics
  • Quality Management

Contact: Dr. Burkhard Breuer, Chief Executive Officer, burkhard.breuer@remove-this.proinnovera.com, Tel: +49-251 270778 - 111, www.proinnovera.com

Data Analytics / Bioinformatic Services

Biomax Informatics - Disease Maps and Knowledge Management for COVID-19 clinical research

Biomax Informatics - Disease Maps and Knowledge Management for COVID-19 clinical research

The Biomax Offering in the field of COVID-19 research activities consists of three parts:

  1. Building up a human Coronavirus Disease Map to support SARS-CoV-2 pathobiology research and vaccine development by combining literature mining with expert curation and semantic data integration.

  2. Providing a knowledge management solution for integration of clinical, laboratory, imaging and high-throughput experimental data with prior knowledge from structured databases and literature mining.

  3. We currently seek partners either interested in contributing SARS-CoV-2 specific data or looking for integrated data and knowledge resources for integrative analysis and machine learning.

Contact: Dieter Maier, Director Project Management, dieter.maier@remove-this.biomax.com,
Tel: +49 - 89 895574-0, www.biomax.com

Datadesk - Electronic data capture solution & software development

Datadesk - Electronic data capture solution & software development

We offer research projects the possibility to use our database software for clinical studies and database development.

We can also support projects with our knowledge in software development and big data analysis.  Depending on the application a prototype can be provided by us within a few days free of charge.

Contact: Jakob Niggel, Founder, Jakob.niggel@remove-this.datadesk.de, Tel: +49 151/52341793, www.datadesk.de

eForce21 - Online Image Annotation Tool for AI Development

eForce21 - Online Image Annotation Tool for AI Development

Offer:
1.    Online Image Annotation Tool for free
2.    Develop computer vision AI

MDs, researchers, medical labs, clinics, scientists, data engineers – if you need an image annotation tool to fight #coronavirus and label e.g. x-ray images, then we offer our platform www.datagym.ai for FREE.
We also offer to develop computer vision AI for diagnostic purposes for FREE if you can provide images.

Contact: Klaus Schlumpberger, CEO, support@remove-this.datagym.ai, Tel: +49 - 89 1250144-00, www.datagym.ai

HS Analysis - Autonomous AI systems for drug development and diagnosis

HS Analysis - Autonomous AI systems for drug development and diagnosis

We are looking for partners from pharm industry for drug development and medical partners from university/hospital for diagnosis and research. COVAI-1 is a software infrastructure, an autonomous AI system for diagnostics, prevention, information, detection system and drug research against corona virus. This system supports medical experts by decision making. It creats reproducible and objective results and gives to medical experts the possibility to train their own AI without programming knowledge and is able to train and volidate themself by adding new information. It runs in a cloud by using low power laptops or secured in a lab at a workstation or at an internal infrastructure of it.

Contact: Sergey Biniaminov, Data Scientist / CEO, Sergey.biniaminov@remove-this.hs-analysis.com, Tel: +49-176-29868666, www.hs-analysis.com   

Independant Data Lab - Biomedical data research for COVID-19 fight

Independant Data Lab - Biomedical data research for COVID-19 fight

We offer a team of data scientists with expertise in biomedical field (bioinformatics, image processing, biostatstics, and machine learning and statistics in general).

Contact: Dr. Tatsiana Aneichyk, CEO, aneichyk@remove-this.independentdatalab.com, Tel: +4915125710007, www.independentdatalab.com   

LMU Bioinformatics - Support for Sequencing Data, Network and Statistical Analysis

LMU Bioinformatics - Support for Sequencing Data, Network and Statistical Analysis

In our research group, we have extensive experience in high-throughput data analysis, in particular for sequencing and network data. A main research focus is the development of bioinformatics methods for transcriptomic analysis of virus-infected cells.

We can offer support for:

  • Statistical analysis and experiment design of large-scale experiments
  • Sequencing data analysis, in particular but not limited to RNA-seq
  • ChIP-seq analysis

Contact: Prof. Dr. Caroline Friedel, Research Group Leader, caroline.friedel@remove-this.bio.ifi.lmu.de, www.bio.ifi.lmu.de/mitarbeiter/caroline-friedel/forschungsgruppe/index.html 

nuco.cloud - cloud computing provider and data centers to provide computing power to fight corona / SARS-CoV-2

nuco.cloud - cloud computing provider and data centers to provide computing power to fight corona / SARS-CoV-2

We are looking for partners, and offering technology and capacities of computing power.
We are a Joint Venture of cloud computing providers and data centers which want to provide our combined computing power to biotechs, universities, scientists etc. which are fighting corona.

Contact: Tobias Adler, CEO, t.adler@remove-this.nuco.cloud, Tel: +49 163 6983 666, www.nuco.cloud

Diagnostics / Testing Capacity / Infrastructure

Advancecor - Aufbau von ELISA-Kapazitäten zur Messung von anti-CoV2 Antikörpern

Advancecor - Aufbau von ELISA-Kapazitäten zur Messung von anti-CoV2 Antikörpern

Gesucht: für CoV2-ELISA Expressionsplasmid für die RBD (receptor binding domain) des CoV2-Spikeproteins und/oder für das CoV2-Nukleokapsid-(N)-Protein, um baldmöglich eine größere eukaryontische Expression beginnen zu können. Am liebsten direkt für FlipIn-CHO-Zellen geeignetes Plasmid, vorzugsweise kloniert mit StrepTag für die Aufreinigung, nehmen aber gerne auch andere Varianten. Noch besser wäre direkt Expressions-Zelllinien für RBD (receptor binding domain) des CoV2-Spikeproteins und/oder für das CoV2-Nukleokapsid-(N)-Protein, die wir in Kultur weiter propagieren dürften. Alternativ auch die gereinigten Proteine.

Contact: Prof. Martin Ungerer, CMO, ungerer@remove-this.advancecor.com, Tel: +49-89 2000 204 10, www.advancecor.com

advanced biolab service - Real Time PCR device

advanced biolab service - Real Time PCR device

We are able to quickly (0-2 days) deliver (sell or rent or provide for free during the crysis period) a refurbished ABI 7300 or 7500 or 7500-Fast Real Time PCR device from our stock to labs, who want to increase their Corona test capacity

Contact: Axel Künzler, Managing Director, kuenzler@remove-this.advancedbiolabservice.com, Tel.: +49 (0) 89 45470050, www.advancedbiolabservice.com

BioVariance - CoVidetect

BioVariance - CoVidetect

We are offering our technological and bioinformatic expertise for the development of comprehensive IT platforms, for handling and analyzing biomedical data gained through COVID-19 testing. We already have a partner for the laboratory preparation of samples. The laboratory equipment is currently expanded to scale-up the workflow.

Contact: Dr., Josef Scheiber, Founder and Managing Director, josef.scheiber@remove-this.biovariance.com, Tel: +49-179-7013682, www.biovariance.com

Biozol - Specific SARS-CoV-2 - detection kit

Biozol - Specific SARS-CoV-2 - detection kit

We are an international distributor with a global partner network. We can provide more than 20 Million products of more than 140 partner companies around the world. We now offer CE IVD certified COVID-19 detection kits for diagnostics.

Contact: Dr. Björn Scheler, Team Leader Marketing and Sales Event, b.scheler@remove-this.biozol.de, Tel: +49-89-37 99 666 92, www.biozol.de   

Colorimetrix - Clinical testing of Immune response evolution with home-kits

Colorimetrix - Clinical testing of Immune response evolution with home-kits

We are sponsoring a small pilot study, looking for a clinical partner that can quickly address and run the clinical study. We will provide the home anti-body testing, and IT platform for analysis.

Contact: Dr. Leo Martinez, Managing Director, leo@remove-this.colorimetrix.com, Tel: +1-3475600037, www.colorimetrix.com

Microcoat - Biomarker evaluation and quantification

Microcoat - Biomarker evaluation and quantification

Microcoat offers the analysis of infectious disease relevant biomarkers, e.g. cytokines on various platforms. We have multiplex panels established on ELLA, MSD and Quanterix platforms.
We have established the Simple Plex COVID-19 Cytokine Storm Panel suitable for measurement of key inflammation markers that are indicative of pathologic inflammatory response.
Benchmark and selection of platforms for the evaluation of new potential biomarkers in early phase and pre-clinical development.
Routine analysis of validated biomarkers in clinical phase (GCP).

Contact: Dr. Katharina Malinowsky, Director Biomarker Services, K.Malinowsky@remove-this.microcoat.de, Tel: +49-8158 9981 32, www.microcoat.de

Microcoat - Development and Manufacturing of Rapid Tests

Microcoat - Development and Manufacturing of Rapid Tests

We are offering expertise in development and manufacturing of ELISA as well as Lateral Flow Assays.
Microcoat is available for cooperation projects for developing diagnostic assays. Based on established technologies and material platforms we offer rapid development with subsequent large-scale manufacturing capabilities (Bulk materials, ELISA and Lateral Flow Tests).

Contact: Dr. Mark-Steven Steiner; Dr. Harald Waltenberger, Director Diagnostic Raw Materials; Director Development, m.steiner@remove-this.microcoat.de; h.waltenberger@remove-this.microcoat.de, Tel: +49-8158 9981 32, www.microcoat.de

Oncare - Epidemic management with myoncare

Oncare - Epidemic management with myoncare

We offer advanced technology for digital mass screening. With its digital healthcare platform myoncare, ONCARE GmbH provides a technical solution for mass screenings. Using a generic QR code, users can register anonymously in the app and complete the screening questionnaire stored there. Based on the score determined from the questions, recommendations for action are automatically made to the user in cooperation with doctors.

Contact: Christian Hieronimi, CEO, info@remove-this.myoncare.com, Tel: +49 - 89 4445 1156, www.myoncare.com

Plazus - Technologies and solutions for infection prevention and control

Plazus - Technologies and solutions for infection prevention and control

Plazus Technologies is a development service provider that also developed a product that is a dedicated communication app for private groups to communicate. Everyone involved in the group, to securely share private information about individuals using blockchain technology.
We would like to extend our protocol and provide the ability to give secure and accurate information and up to date on someone's health history and status.

Contact: Galya Westler, CEO and Co-founder, Galya@remove-this.plazus.com,
Tel: whatsapp: +1604-649-4171, +49-160-1638-171 (please send email firstly to coordinate a call), www.plazus.com

Securetec Detektions-Systeme - Lateral flow test co-development and production

Securetec Detektions-Systeme - Lateral flow test co-development and production

We offer production capacities for the mass production of lateral flow tests.
We`re looking for partners to develop corona-virus piont of care rapid tests.
We are experts in detecting analytes in saliva or sputum.
We are experts in saliva/ blood/plasma sample preparation for lateral flow tests.
We offer a state-of-the-art handheld device for the electronic readout of lateral flow tests.
We have and offer our know-how and experince of 25 years in developing and producing lateral flow tests.

Contact: Dr. Torsten Stadthagen, Head of Development,  stadthagen@remove-this.securetec.net, www.securetec.net

TRIGA-S - Supporting manufacturers during evaluation of innovative COVID-19 diagnostic tests

TRIGA-S - Supporting manufacturers during evaluation of innovative COVID-19 diagnostic tests

We are supporting diagnostic manufacturers to get their COVID-19 tests on the market soon according to the EU In Vitro Diagnostic Directive, the new EU In Vitro Diagnostic Regulation and US-FDA regulations.

Contact: Dr. Jens Hain, Director Business and Clinical Development, Jens.Hain@remove-this.triga-s.de, Tel: +49- 8847-69578-45, www.triga-s.de

Lab Supplies / Production Capacities

Freyer & Siegel Elektronik - Development and production of components and devices

Freyer & Siegel Elektronik - Development and production of components and devices

We are developer and producer of industrial, medical and laboratory equipment according to customers orders. So we are certified according to DIN EN ISO 13485: 2016 and DIN EN ISO 9001:2015. We have special experience with sensors, electronic processing and actuators, as well as with the user interface. Our thinking is interdisciplinary and we take care of everything, as well as the device approval. We are happy to offer our services in the area of development and production of components and devices.

Contact: Sönke Paschko, Position Head of R & D, soenke.paschko@remove-this.freyersiegel.de, Tel: +49-3302 / 79-121-34, www.freyersiegel.de

Helmut Schweyer Feinmechanik - Capacities and Experience

Helmut Schweyer Feinmechanik - Capacities and Experience

We offer our capacities and experience:

Manufacturing of complex turned and/or milled medical parts made of different materials (according to DIN ISO 9001:2015).

Contact: Stephanie Toch, QMB, Stephanie.toch@remove-this.schweyer-feinmechanik.de, Tel: +49-89/92927766-60, www.schweyer-feinmechanik.de

Oxxid - Engineering & design support for product development, prototyping and production

Oxxid - Engineering & design support for product development, prototyping and production

Offering expertise in the field of product development:

  • Product development services for appliances and consumables
    - design, engineering, CAD, UX, UI, ergnomics
  • Production support
    - (rapid) prototyping, production of devices and mock-ups
    - supplier network for sample and series production

We offer technical support backing up your core business development.

Contact: Stefan Reichl, CEO, stefan.reichl@remove-this.oxxid.de, Tel: +49-89 55 26 78 82,  +49-171 69 54 197, www.oxxid.de

Ritter - Plastic consumables for laboratories

Ritter - Plastic consumables for laboratories

We are offering:
•    deepwell plates
•    microtiter plates
•    conductive robotic pipet tips
•    transparent robotic pipet tips
•    racked microtubes
•    dispenser tips

Contact: Andreas Rauch, Key Account Manager, andreas.rauch@remove-this.ritter-online.de,
Tel: +49-1718315567 or +49-82325003720, www.ritter-medical.de

Zollner Elektronik - Manufacturing Solutions for Medical Devices

Zollner Elektronik - Manufacturing Solutions for Medical Devices

Do you need manufacturing solutions or more capacity for your medical products? Do you need manufacturing according to the specific regulations like ISO13485 or FDA?
Zollner has been providing manufacturing solutions of complex systems to the medical industry for more than 25 years.

Contact: Markus Reitmeier, Senior New Business Development Manager, Markus_reitmeier@remove-this.zollner.de, Tel: +49 99 44 201 7542, www.zollner.de

 

 

Protection Equipment / Disinfection

Bionic Surfaces - Does it make sense to equip protection clothing with antiviral compounds?

Bionic Surfaces - Does it make sense to equip protection clothing with antiviral compounds?

Offer: IF experts APPROVE above question - bionic surfaces – is in a position to arrange surface modification of non woven fabrics with potential antiviral compounds like tetrahydrozoline, chlorothiazide chloroquine and formoterol as e.g. pointed out in Pharmacoinformatics and molecular dynamic simulation studies reveal potential inhibitors of SARS-CoV-2 main protease 3CLpro; MA Alamri, MT ul Qamar, SM Alqahtani - 2020 – preprints.org

Contact: Dr. med. Rolf Siegel, rolf@remove-this.bionicsurfaces.de, Tel: +49-931-275868, www.bionicsurface.com

ScintHealth - SARS CoV 2 Inactivation using UV-C

ScintHealth - SARS CoV 2 Inactivation using UV-C

Request:
Partners having lab infrastructure (S3 lab) and personnel to perform tests with SARS CoV 2
Partners having access to active SARS CoV 2 viruses for experiments
Expertise on quantification of viruses on surfaces.
Offer:
Hardware (UV-C incl. circuitry and UV spectrometers) for irradiating samples and measuring UV light intensity.
Based on the literature other corona viruses like MERS-CoV and SARS-CoV can be successfully inactivated using UV C alone.
UV C disinfection of surfaces with potential SARS CoV 2 viruses has and is been applied already during the current crisis. However, to our knowledge, no quantitative evaluation has been reported in the literature. We propose to determine empirically the dose/inactivation curve for SARS CoV 2 for different UV-C wavelengths. Thus we expect to deduct doses that are effective for the disinfection of surfaces inside hospitals, in public transportation, elevators, etc.

Contact: Dr. Thomas Wendler, CEO, thomas.wendler@remove-this.scinthealth.com, Tel: +49 (176) 82179775

RAS - Nanosilver based active substance with potential antiviral efficacy

RAS - Nanosilver based active substance with potential antiviral efficacy

We at RAS AG developed an antimicrobial agent based on nanosilver over 15 years ago, which is now sold for various applications and is marketable compliant with the EU Biocide Regulation.
The nanosilver active substance exhibits antiviral efficacy:
Our nanosilver based formulations recently have been tested efficient against different members of the family Coronaviridae.
RAS AG offers technologies to create coatings on various substrates, that contain the antiviral substance. The active substance can be incorporated into materials for long lasting effects.

Contact: Theresa Sigritz, Sales Manager agpure, ts@remove-this.ras-ag.com, Tel: +49-941/60 717-318, www.ras-ag.com

We are searching for Virologists or laboratory that have experience in the evaluating the efficacy of antiviral substances or surfaces that incorporate those substances. We are developing new products and treated articles, which include antiviral substances. The tests have to be performed with SARS-CoV-2. As result the efficacy has to be quantified at best in a certain percentage of inhibition or log-step reduction of the viral vitality/infectivity. There are different test methods available, we are open to discuss.

Contact: Gregor Schneider, Authorized Head of Business unit agpure®, gs@remove-this.ras-ag.com, Tel: +49-941/60 717-305, www.ras-ag.com

Research / Drug Discovery Tools, Reagents or Services

2Bind - Biophysical analytical tools in early COVID19 drug discovery

2Bind - Biophysical analytical tools in early COVID19 drug discovery

2bind has a broad portfolio of different biophysical analytical tools to study drug – target interactions. The range of assay cover biophysical HIT ID (HTS) via HIT validation to characterization of HITs.
Potential hits for COVID19 relevant targets could be identified and validated using different biophysical methods (MST, nanoDSF, ITC, BLI).

Contact: Dr. Thomas Schubert, CEO,  schubert@remove-this.2bind.com, +49 941 20000890 www.2bind.com/drug-discovery

Biozol - Specific SARS-CoV-2 - COVID-19 antibodies, proteins and detection kits

Biozol - Specific SARS-CoV-2 - COVID-19 antibodies, proteins and detection kits

We are an international distributor with a global partner network. We can provide more than 20 Million products of more than 140 partner companies around the world. We are working under high pressure to continously update our webshop with products specifically for research and diagnostics on SARS-CoV-2 and COVID-19.

Contact: Dr. Björn Scheler, Team Leader Marketing and Sales Event, b.scheler@remove-this.biozol.de, Tel: +49-89-37 99 666 92, www.biozol.de   

Cellassays - Label-free test for efficacy of antiviral substances toward cellular models with microphysiometry

Cellassays - Label-free test for efficacy of antiviral substances toward cellular models with microphysiometry

Cellassays GmbH offers label-free tests for efficacy of antiviral substances toward cellular models with microphysiometry.

Contact: Dr. Joachim Wiest, CEO, wiest@remove-this.cellasys.com, Tel: +49-8394-257929, www.cellasys.com

CellTool - Raman-Trapping-Microscope BioRam® for fast detection of pathogens

CellTool - Raman-Trapping-Microscope BioRam® for fast detection of pathogens

Looking for partners:
We have coupled a 785nm Raman excitation laser into an inverted digital microscope for fast and easy single cell analysis without any labelling or staining. Due to the unique laser coupling optical trapping features are induced simultaneously that attract cells/bacteria/exosomes/viruses and hold them in position during Raman spectra acquisition. Optional fluorescence modules allow comparison with routine staining procedures.

Contact: Dr. Karin Schütze, Position CSO, k.schuetze@remove-this.celltool.de, Tel: +49-172-754 7728, www.celltool.de

EpiQMAx - Mass spectrometry for antibody analytics and small molecule testing for COVID19

EpiQMAx - Mass spectrometry for antibody analytics and small molecule testing for COVID19

EpiQMAx offers the analysis of antibodies and small molecules by means of mass spectrometry. In particular, we can characterize biological and biophysical parameters very precisely. Thereby, we support all research activities for COVID19 and offer our platform technology for drug discovery purposes.

Contact: Dr. Moritz Völker-Albert, CEO, Voelker-albert@remove-this.epiqmax.de, Tel: +49-89 2153 5730, www.epiqmax.de

European Vaccine Initiative – R&D support for vaccine development

European Vaccine Initiative – R&D support for vaccine development

What can we offer:

  • A fully equipped project management office
  • Expertise in pre-clinical and early phase clinical development of vaccines, incl. support with setting up e.g. pre-clinical assays, GMP manufacture, clinical trials
  • A global partner network consisting of Academic Institutions (public and private), Vaccine Companies (human and veterinary vaccines, big pharma, SMEs, CMOs, CROs), Regulatory Agencies, etc.
  • High Quality Technical Services to support the development of vaccines through the H2020 funded TRANSVAC2 project (www.transvac.org)
  • Training on various aspects of vaccine development either directly through EVI (please enquire) or through the H2020 funded TRANSVAC2 project (www.transvac.org)

What are we looking for:

  • Collaborators who are interested in partnering with EVI for the development of a Covid-19 vaccine
  • Organisations in need of technical services and training

Contact: Dr Stefan Jungbluth / Dr Nicola Viebig, Head of Business Development / Chief Scientific Officer, stefan.jungbluth@remove-this.euvaccine.eu / nicola.viebig@remove-this.euvaccine.eu, Tel: +49-176-31615202 / +49-176-31615203, www.euvaccine.eu

Fraunhofer EMFT/IBMT- Monitoring cell-based neutralization assays

Fraunhofer EMFT/IBMT- Monitoring cell-based neutralization assays

We are offering a label-free, impedance-based platform to monitor the host cell response in assays addressing the neutralizing capacity of antibodies against Covid-19.

Contact: Prof. Dr. Joachim Wegener, Joachim.Wegener@remove-this.emft.fraunhofer.de, Tel: +49-941-943-4546 or +49-179-4872144, www.emft.fraunhofer.de/de/kompetenzen/innovative-sensorloesungen/zell-basierte-sensorik.html, www.ibmt.fraunhofer.de/de/ibmt-kernkompetenzen/ibmt-medizinische-biotechnologie/ibmt-bioprozesse-bioanalytik.html

HMGU - A mouse challenge model to test the efficacy and protective capacity of vaccine candidates

HMGU - A mouse challenge model to test the efficacy and protective capacity of vaccine candidates

We can apply recombinant murine gammaherpesvirus 68 (MHV-68) as a challenge virus in mice to test the efficacy of heterologous candidate human vaccines.

Contact: Prof. Dr. Heiko Adler, Deputy Head of Research Unit, Research Group Leader, h.adler@remove-this.helmholtz-muenchen.de, Tel: +49-89-3187-1327, www.helmholtz-muenchen.de/lrr/forschung/adler-lab/scientific-focus

INCYTON - Automated cell-based real-time assay platform with multiple label-free sensors

INCYTON - Automated cell-based real-time assay platform with multiple label-free sensors

We are offering our technology for vaccine development, viral investigations and pathogen-target cell characterization.
We are looking for partners to develop further established methods and who are in the preclinical in vitro testing of vaccine candidates.

Contact: Dr. Martin Strehle, CEO, covid19@remove-this.incyton.com, Tel: +49-89-203 241 42 71, www.incyton.com

Iris Biotech - Chemical Synthesis Service

Iris Biotech - Chemical Synthesis Service

Particular for any type of linker technology between biomolecules, antibodies, proteins etc., and small molecules. Linker can be designed that they are stable in all physiological environments or stable in plasma and fragmentize in lysosome.

Contact: Dr. Thomas Bruckdorfer, CSO & Vice President Business Development, thomas.bruckdorfer@remove-this.iris-biotech.de, Tel: +49 9231 97121-10, www.iris-biotech.de

LMU Institute of Laboratory Medicine - Therapeutic drug monitoring of antiviral medication and quantification of potential diagnostic small molecule biomarkers

LMU Institute of Laboratory Medicine - Therapeutic drug monitoring of antiviral medication and quantification of potential diagnostic small molecule biomarkers

Offering: Liquid chromatography tandem mass spectrometry (LC-MS/MS) analysis of different antiviral agents and other small molecule compounds from human serum or plasma.

Therapeutic Drug Monitoring of antiviral substances for treatment of COVID-19 patients may be important in clinical studies and may offer therapeutic advantages in standard clinical care. For this purpose, quantification methods will be developed according to the following substance prioritization list:
1. Camostat mesylate, 2. Remdesivir, 3. Favipiravir, 4. Chloroquine/ Hydroxychloroquine, 5. Arbidol, 6. Ritonavir/ Lopinavir, 7. Ribavirin/ Sofosbuvir
Beyond these drug target analytes, the available technical platform could be used to quantify small molecule compounds with potential added diagnostic value in the context of severe viral infections.

Contact: Prof. Dr. med. Daniel Teupser, Director, Institute for Laboratory Medicine, Daniel.Teupser@remove-this.med.uni-muenchen.de, Tel: + 49 89 4400 - 73210, www.klinikum.uni-muenchen.de/Institut-fuer-Laboratoriumsmedizin/de/

MvP Institute - From intra-viral and virus-host protein-protein interactions to broad-spectrum antivirals against Coronaviruses

MvP Institute - From intra-viral and virus-host protein-protein interactions to broad-spectrum antivirals against Coronaviruses

Offer:
we are a virology/molecular biology lab working on Coronaviruses for ~15 years
Request:
1) Motivated students in bioscience field with benchwork experience (molecular biology, cell culture) for internships, bachelor, masters, PhD work
2) Computer-aided drug design modellors for inhibitor modelling of our most promising coronavirus-host protein-protein interactions
3) Organic chemistry synthesis of small cyclic peptides

Contact: Dr. Albrecht von Brunn, Research group leader, vonbrunn@remove-this.mvp.lmu.de, Tel: +49-89-218072839, http://www.mvp.uni-muenchen.de/forschung/virology/research-group-von-brunn/ 

Nanotemper - High throughput biophysical technologies

Nanotemper - High throughput biophysical technologies

We offer easy to use biophysical technologies with low sample consumption and high throughput.
Monolith & Dianthus instruments to measure the binding & affinity of molecules to viruses (dose-response) and molecular targets (interaction studies).

Contact: Dr. Phillip Baaske, CEO, Philipp.baaske@remove-this.nanotempertech.com, Tel: +49 89 4522895100, www.nanotempertech.com

OmicScouts - Chemical proteomics support faster discovery and development of drugs and vaccines

OmicScouts - Chemical proteomics support faster discovery and development of drugs and vaccines

OmicScouts combines cell biology, biochemical and mass spectrometry-based proteomics expertise, computational biology capabilities and drug discovery experience to support drug discovery projects fast and efficient.

Contact: Dr. Hannes Hahne, CEO, hannes.hahne@remove-this.omicscouts.com, Tel: +49-8161-976289-0, www.omicscouts.com/en/covid-19  

PAN-Biotech - Offering expertise and production capacity

PAN-Biotech - Offering expertise and production capacity

Expertise: cell culture media development; sourcing biochemical compounds; manufacture sterile products in industrial scale under ISO 9001 and 13485 standards.
Capacity: 10 000 L sterile filtration per week

Contact: Pascal Zimmermann, CEO, info@remove-this.pan-biotech.de ,www.pan-biotech.de

PEPperPRINT - Serology Screening for SARS-CoV-2 antibodies on Peptide Microarrays

PEPperPRINT - Serology Screening for SARS-CoV-2 antibodies on Peptide Microarrays

  • Research product: PEPperCHIP® SARS-CoV-2 Proteome Microarray
  • Platform technology for the fast-track generation of high-density peptide microarrays covering whole virus proteomes or selected virus antigens
  • Serum antibody fingerprint analysis of IgG, IgM and IgA antibody responses on the epitope level in Covid-19 patient sera for IVD test development
  • Immune monitoring of antibody responses in SARS-CoV-2 vaccination trials
  • Epitope analysis services of prognostic or neutralizing antibodies in patient sera to support vaccine development
  • Epitope mapping services of anti-SARS-CoV-2 antibodies

We are looking for:

  • Academic groups or biotech/pharma companies working on anti-SARS-CoV-2 antibodies
  • Academic groups or diagnostic companies involved in IVD development
  • Academic groups or pharmaceutical companies involved in SARS-CoV-2 vaccine trials

Contact: Dr. Volker Stadler, CEO, volker.stadler@remove-this.pepperprint.com, www.pepperprint.com 

PolyQuant - Protein Analysis Reagents and Bioinformatics Services for COVID-19 Research and Development

PolyQuant - Protein Analysis Reagents and Bioinformatics Services for COVID-19 Research and Development

Offering profound expertise and technology for protein related vaccine and drug development;
Looking for partners in related vaccine and drug discovery development or research

QconCAT polypeptides are valuable tools for vaccine and virus research (see below). Apply QconCAT polypeptides in targeted proteomics for SARS-Cov-2/COVID-19 experiments using Q-peptides (unique proteotypic peptides) for quantification by mass spectrometry.
Custom COVID-19 protein expression or expression of protein fragments for SARS-Cov-2 (e.g. SPIKE, ORF3a, Envelope protein, Membrane glycoprotein, ORF8, Nucleocapsid phosphoprotein) or host receptors (e.g. ACE2_HUMAN)
LC-MS calibration kits to standardize workflows between experiments and across different laboratories.

Design and expression of a QconCAT protein to validate Hi3 protein quantification of influenza vaccine antigens. Smith D. et al., J Proteomics. 2016 Sep 2;146:133-40

Contact: Dr. Andrea Bhangu-Uhlmann, CEO, bhangu-uhlmann@remove-this.polyquant.com, Tel: +49 (0) 9405 9699910, www.polyquant.com

Sciomics - Multiplex protein profiling services for acceleration of COVID-19 research

Sciomics - Multiplex protein profiling services for acceleration of COVID-19 research

Sciomics supports COVID-19 research with a focus on:

  • COVID-19 disease understanding (e.g. immune profiling of patient cohorts)
  • Development of novel therapeutics against COVID-19 (e.g. benchmarking of compounds, biomarker discovery)
  • Development of vaccines against SARS-COV-2 (e.g. vaccination response analysis, identification of COVID-19 epitopes)

Assay specifics:

  • up to 1300 proteins profiled in parallel
  • Minimal sample amount required
  • Complete analysis service from sample to study report

All assays can be complemented by a SARS-COV-2 proteome wide peptide array.

Contact: Dr. Ronny Schmidt, Head of Contract Research, info@remove-this.sciomics.de,
www.sciomics.de

Twist Bioscience - Synthetic RNA controls and NGS Target Enrichment

Twist Bioscience - Synthetic RNA controls and NGS Target Enrichment

Offering consumables: Synthetic DNA / RNA products (genes, fragments, oligo pools, libraries) and NGS target capture kits.

Fully synthetic RNA positive controls for SARS-COV-2 (full genome)
SARS-COV-2 NGS Target Enrichment kits
High Throughput DNA Synthesis (DNA fragments, genes, cloned genes)
Oligo Pools, DNA Variant Libraries
Link to our COVID-19 research tools: www.twistbioscience.com/coronavirus-research-tools

Contact: Oliver Latz, NGS Sales specialist, olatz@twistbioscience.com, Tel: 49-(0)162-526-843-0, https://www.twistbioscience.com 

Universität Würzburg Virologie - Test system for new antiviral compounds

Universität Würzburg Virologie - Test system for new antiviral compounds

We can offer to test compounds in cell culture for toxicity and for suppression of COVID19. We are looking for partners who have components, such as new polymerase or protease inhibitors, which have not been tested so far. We have established screening for antiviral compounds in different cell culture models. In addition, we have access to a P3/S3 facility and have already obtained permission to work with wild-type COVID-19.

Contact: Prof. Dr. Jochen Bodem / Dr. Maria Steinke, AG-Leiter, Jochen.Bodem@remove-this.vim.uni-wuerzburg.de, Tel: +49-931-3181509, www.virologie.uni-wuerzburg.de/virologie/ags-virologie/ag-bodem/arbeitsgebiete/a-anti-viral-drugs/

Samples

LMU Dr. von Hauner Children's Hospital - Search for lymphocytes, peptides and HLA typing

LMU Dr. von Hauner Children's Hospital - Search for lymphocytes, peptides and HLA typing

Request:
We are urgently looking for people who could provide:
- lymphocytes or whole blood samples from people who have been tested CoV-2 positive.
- customized synthetic peptides, length approximately 15 peptides. About 1 mg, do NOT need to be high-purified.
- fast (48 hours) HLA typing for about 5 samples, only A B C classification required

Contact: Dr. Ramona Krauss, Study Coordinator, Ramona.Krauss@med.uni-muenchen.de, Tel: +49 89 4400 52990

Mikrogen - Serological Coronavirus/SARS samples for validation of our test development

Mikrogen - Serological Coronavirus/SARS samples for validation of our test development

We offer already a well-received Multiplex Real-time PCR assay ampliCube Coronavirus Panel. In addition, we are currently developing tests for the serological antibody detection of SARS-CoV-2. This will be both a screening test in our recomWell format (ELISA platform) and a confirmation test based on a strip test (recomLine).
We would need blood samples from SARS-CoV-2 patients and also serological patient samples for SARS-1 as well as seasonal corona viruses for differentiation.

Contact: Dr. Patrick Schreiner, Head of Research & Development, schreiner@remove-this.mikrogen.de, Tel: +49 - 8954801-180, www.mikrogen.de

Therapy

bene pharmaChem - Second use of PPS to cope with cytokine (storm) related complications of COVID-19

bene pharmaChem - Second use of PPS to cope with cytokine (storm) related complications of COVID-19

Offer:    
approved oral drug formulation and injectable study drug formulations for clinical trials and in vitro studies.

Request: Partners for clinical studies
Eventually: partners providing anti-viral drugs

Contact: Dr. K. P. Maag, Senior Director R&D, k.maag@remove-this.bene-pharmachem.de, Tel: +49-8171-9825-100, www.bene-pharmachem.de/en/product/

 

 

Cfm Oskar Tropitzsch - new drug against COVID-19 and a number of other viruses

Cfm Oskar Tropitzsch - new drug against COVID-19 and a number of other viruses

We are looking for pharmaceutical companies or investors which have the ability to speed up the development of our new drug (currently R&D substance) against the SARS class of compounds of course as well against COVID-19 and a number of other viruses (i.e. Zika).

Contact: Michael Schaeffler, Authorised Signatory – Project Manager, Michael.Schaeffler@remove-this.cfmot.de, Tel:+49 9231 961924/+49 17610 961924, www.cfmot.de

HMGU - Neutralizing fully human antibodies against Covid-19

HMGU - Neutralizing fully human antibodies against Covid-19

We are looking for partners for pre-clinical validation of the antibodies as well as for large-scale production (ideally, GMP compliant)

Contact: Prof. Dr. R. Zeidler, Group Leader, zeidler@remove-this.helmholtz-muenchen.de, Tel: +49-89-3187-1296, www.helmholtz-muenchen.de/agv

Terraplasma Medical - Cold atmospheric plasma for inactivation of SARS-CoV-2 and prevention of super-infections at mechanically ventilated patients.

Terraplasma Medical - Cold atmospheric plasma for inactivation of SARS-CoV-2 and prevention of super-infections at mechanically ventilated patients.

We offer a medical device for the significant reduction of bacteria and viruses in the upper respiratory tract at mechanically ventilated patients.
We are looking for lab-capacities and (pre-) clinical partners to evaluate the efficacy of cold plasma against SARS-CoV-2 in-vitro. Further we are looking for clinical partners for in-vivo testing and evaluation of SARS-CoV-2 reduction and prevention of super-infections.

Contact: Jens Kirsch, Geschäftsführer, jens.kirsch@remove-this.terraplasma-medical.de, Tel:    +49 - 89 588 0 553 0, www.terraplasma-medical.de

Vivoryon Therapeutics - (cell-based) assays on corona virus

Vivoryon Therapeutics - (cell-based) assays on corona virus

Vivoryon Therapeutics offers our small molecule compounds for testing of efficacy against corona virus.
We are looking for a partner with capability of testing small molecules in a disease relevant context.

Contact: Dr. Christine Wenzkowski, Senior Director Business Development, christine.wenzkowski@remove-this.vivoryon.com, +49 -1728240951, www.vivoryon.com

Vaccine Development

Cevec - Cell lines for production of COVID-19 vaccine

Cevec - Cell lines for production of COVID-19 vaccine

Offer:
CEVEC offers the CAP® cell line for COVID-19 vaccine development and production. The human suspension cell line (and derivatives thereof) has been proven in a variety of applications as a superior production cell line for vaccines, both complex peptides/ proteins as well as viral vaccines. It is particularly well suited for production of vaccines based on Adenoviral vectors, as it avoids RCA formation.

Contact: Dr. Ulrich Kettling, CBO, bizdev@remove-this.cevec.com, Tel: +49-221-460 208 00, www.cevec.com